Concurrent Durvalumab Plus Chemo/RT Does Not Improve Efficacy in Stage III NSCLC

News
Article

For patients with unresectable stage III NSCLC, concurrent durvalumab with chemotherapy/radiation did not show an efficacy improvement.

For patients with unresectable stage III NSCLC, concurrent durvalumab with chemotherapy/radiation did not show an efficacy improvement.

For patients with unresectable stage III NSCLC, concurrent durvalumab with chemotherapy/radiation did not show an efficacy improvement.

Efficacy was not improved with concomitant durvalumab (Imfinzi) during chemotherapy and radiation (RT) for patients with stage III unresectable non-small cell lung cancer (NSCLC), according to results from the phase 3 EA5181 trial presented at the 2025 World Conference on Lung Cancer.

In the durvalumab arm, the median overall survival (OS) was 41.5 months (95% CI, 34.4-not reached [NR]) vs 39.4 months (95% CI, 33.4-NR) for patients in the chemotherapy/RT arm (HR, 1.03; 95% CI, 0.80-1.32; P = .83). The median progression-free survival (PFS) was 15.5 months in the durvalumab arm (95% CI, 13.9-22.1) vs 16.4 months (95% CI, 12.0-20.2) in the chemotherapy/RT arm (HR, 1.05; 95% CI, 0.86-1.29; P = .65).

“In patients with unresectable, stage III [NSCLC], the addition of concomitant durvalumab during the course of chemotherapy/radiation did not improve OS, did not improve PFS, did not change the recurrence patterns or ORRs [overall response rates], and did not increase toxicity,” John M. Varlotto, MD, professor and chief of Radiation Oncology at Marshall Health, stated during the presentation.

Patients were randomly assigned 1:1 to receive either platinum doublet durvalumab at 750 mg every 2 weeks plus 3 concurrent rounds of RT at 60 Gy or platinum doublet chemotherapy with concurrent RT at 60 Gy. Patients could then transition to consolidation durvalumab at 1500 mg every 4 weeks for 1 year from the end of chemotherapy/RT. This transition could occur within 2 weeks, but may be delayed up to 45 days, depending on whether patients’ toxicities are not grade 2 or less.

Patients were stratified by planned chemotherapy, age, sex, and disease stage. Patients were eligible for treatment if they had unresectable stage IIIA to C NSCLC and had an ECOG performance status of 0 to 1.The primary end point was OS, with secondary end points being PFS, toxicity, ORRs, and recurrence patterns.

A total of 662 patients were randomly assigned to either arm. Varlotto noted the study had an 82% power to detect a 25% reduction in the OS HR rate of 0.01631 to 0.01223, and a 1-sided alpha level of 0.025.

The median follow-up was 29.9 months (95% CI, 28.4-33.1). In the durvalumab arm, 335 patients were enrolled, with 305 completing treatment, and 277 moving on to consolidation. In the chemotherapy/RT arm, 327 patients were enrolled, 300 completed treatment, and 277 moved on to consolidation.

Across both arms, 60.6% of patients were male, the median age was 67.1 years (range, 37.6-89.4), and 50.6% of patients had stage IIIA disease. Additionally, 48.7% of patients had adenocarcinoma, 53.3% were former smokers, and 82.5% were given carboplatin/paclitaxel.

A total of 45.4% of patients had experienced disease progression in the durvalumab arm, and 44.0% had it in the chemotherapy/RT arm. Local recurrence was noted in 55.9% vs 49.6% (P = .34), and radiation in-field recurrences were observed in 28.6% vs 28.4% (P = .98).

Prior to consolidation, the ORR was 51.3% in the durvalumab arm and 47.1% in the chemotherapy/RT arm (P = .28), while in consolidation, the ORR was 71.5% vs 67.1% (P = .31). In both arms, the median number of consolidative cycles of durvalumab was 10.

In the durvalumab arm, adverse effects (AEs) of any grade occurred in 99.1% vs 98.7% in the chemotherapy/RT arm, while grade 3/4 AEs were noted in 67.7% vs 62.2%., Serious AEs were observed in 3.6% vs 3.5%, and AEs leading to treatment discontinuation occurred in 19.0% vs 16.5%.

The most common grade 3 to 5 treatment-related AEs in the durvalumab and chemotherapy/RT arms were lymphocyte count decrease (50% vs 45%), white blood cell count decrease (22% vs 27%), esophagitis (21% vs 27%), neutrophil count decrease (16% vs 14%), and pneumonitis (12% vs 5%).

Reference

Varlotto JM, Xie Y, Pennell N, et al. ECOG-ACRIN EA5181: phase 3 trial of concurrent and consolidative durvalumab vs consolidation durvalumab alone for unresectable stage III NSCLC. Presented at the 2025 World Conference on Lung Cancer; Barcelona, Spain; September 6-9, 2025. Abstract PL-3.04.

Recent Videos
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
An easy-to-access database allows one to see a patient’s cancer stage, prior treatment, and survival outcomes in a single place.
Better defining which patients with GI cancers are preferred candidates for adoptive cellular therapies may help optimize outcomes.
A consolidated database may allow providers to access information on a patient’s prior treatments and genetic abnormalities all in 1 place.
A study presented at ASTRO 2025 evaluated the feasibility of using a unified cancer database to consolidate information gathered across 14 institutions.
Related Content